☆ 4.3 Review

Extended dosing of monoclonal antibodies in multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL (2022)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis

Giulio Disanto et al.

Summary: De-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis is safe and leads to clinical and radiological stability over 12 months. Serum NfL concentration remains stable, but higher rituximab load negatively affects IgG concentrations, with IgG deficient patients at higher risk of infections.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Pharmacology & Pharmacy

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

Ekaterina Gibiansky et al.

Summary: The study assessed the pharmacokinetics and pharmacodynamics of ocrelizumab in patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). Results showed that the serum concentration of ocrelizumab was accurately described by a 2-compartment model with time-dependent clearance, with body weight as the main covariate. B-cell depletion in blood was also found to be greater with higher exposure to ocrelizumab.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Clinical Neurology

Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis

Malin Boremalm et al.

Summary: Rituximab is safe and effective in treating RRMS, with long-term effects on inflammatory disease activity. Disease reactivation is rare in MS patients who discontinued treatment, and low-dose rituximab (< 1000 mg yearly) is sufficient to maintain suppression of inflammatory disease activity in stable patients.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Stefania Federica De Mercanti et al.

Summary: Extending the dosing interval of natalizumab (EID) does not increase the risk of active lesions on MRI compared to standard interval dosing (SID) in JCV-positive multiple sclerosis patients.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

Barbara Barun et al.

Summary: The study evaluated the effects of delaying ocrelizumab infusions during the COVID-19 pandemics in people with multiple sclerosis. It was found that delaying the dosing of ocrelizumab did not have clinical consequences, but was an independent predictor of B cell repopulation.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

F. Tazza et al.

Summary: During the SARS-CoV-2 pandemic, personalized delayed protocol for ocrelizumab infusions in RRMS patients was effective in guiding re-infusions based on immunophenotyping, showing no compromise in short-term efficacy due to treatment delays.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis

Maria Trojano et al.

Summary: The study aimed to examine the efficacy, safety, and tolerability of natalizumab administered via various regimens in RRMS patients. The results showed that natalizumab 300 mg subcutaneous Q4W was comparable to 300 mg intravenous Q4W dosing with respect to efficacy, pharmacokinetics/pharmacodynamics, and safety.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Immunology

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

Javier Riancho et al.

Summary: Observational study on the long-term effectiveness of natalizumab with extended interval dosing (EID) in multiple sclerosis patients treated for over 7 years showed that EID preserved treatment efficacy and prevented disability worsening during follow-up. Patients treated with natalizumab for the first time showed slightly better response to EID therapy compared to those previously treated with other immunosuppressive drugs.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Clinical Neurology

Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases

N. R. Oksbjerg et al.

Summary: The risk of infections requiring hospitalization in patients treated with anti-CD20 antibodies was independently associated with comorbidities, treatment duration, and higher EDSS scores. Risk of VZV infection was independently associated with lymphopenia. Further studies are needed to explore strategies for reducing infection risk in these patients, especially for older patients, those with higher disability levels, and those with longer treatment durations.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Leoni Rolfes et al.

Summary: The study found that extending interval dosing of ocrelizumab for RRMS patients during the COVID-19 pandemic did not result in decreased effectiveness compared to standard interval dosing. Both treatment regimens were effective in maintaining clinical stability and preventing disease progression.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Clinical Neurology

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron et al.

Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience

Chiara Zecca et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico et al.

NEUROTHERAPEUTICS (2020)

Add to Collection

Article Clinical Neurology

Pharmacodynamics of natalizumab extended interval dosing in MS

Lana Zhovtis Ryerson et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Tailoring B cell depletion therapy in MS according to memory B cell monitoring

Giovanni Novi et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial

Zoe L. E. van Kempen et al.

NEUROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

Clara Grazia Chisari et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Add to Collection

Review Clinical Neurology

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

David Baker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS

Angelo Ghezzi et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)

Add to Collection

Article Clinical Neurology

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Zoe L. E. van Kempen et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Zoe L. E. van Kempen et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

Add to Collection

Article Clinical Neurology

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study

Amit Bar-Or et al.

NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Efficacy and safety of natalizumab extended interval dosing

Bassem Yamout et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

Kumar Kandadi Muralidharan et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Article Clinical Neurology

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Tatiana Plavina et al.

NEUROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Clinical Neurology

α4-integrin receptor desaturation and disease activity return after natalizumab cessation

Tobias Derfuss et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection

Article Pharmacology & Pharmacy

A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis

Tatiana Plavina et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Extended interval dosing of natalizumab in multiple sclerosis

L. Zhovtis Ryerson et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)

Add to Collection

Article Clinical Neurology

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

Pierre de Flon et al.

NEUROLOGY (2016)

Add to Collection

Article Clinical Neurology

Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy

Jonatan Salzer et al.

NEUROLOGY (2016)

Add to Collection

Article Clinical Neurology

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study

Per S. Sorensen et al.

NEUROLOGY (2014)

Add to Collection

Article Clinical Neurology

Extended interval dosing of natalizumab: a two-center, 7-year experience

Roberto Bomprezzi et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Ludwig Kappos et al.

LANCET (2011)

Add to Collection

Article Clinical Neurology

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis - A 52-week phase II trial

R. T. Naismith et al.

NEUROLOGY (2010)

Add to Collection

Article Clinical Neurology

Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial

Kathleen Hawker et al.

ANNALS OF NEUROLOGY (2009)

Add to Collection

Article Clinical Neurology

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or et al.

ANNALS OF NEUROLOGY (2008)

Add to Collection

Article Medicine, General & Internal

B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

CH Polman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Medicine, General & Internal

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

RA Rudick et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Clinical Neurology

Randomized multicenter trial of natalizumab in acute MS relapses - Clinical and MRI effects

PW O'Connor et al.

NEUROLOGY (2004)

Add to Collection

Article Medicine, General & Internal

A controlled trial of natalizumab for relapsing multiple sclerosis.

DH Miller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.